FFAR4 Antibody

What is FFAR4 and why is it important in research?

FFAR4 (Free Fatty Acid Receptor 4), also known as GPR120, is a G-protein-coupled receptor that preferentially binds to long-chain saturated and unsaturated fatty acids. This receptor is involved in numerous biological functions including cell membrane maintenance, metabolism, insulin response, and the inflammatory cascade . FFAR4 has emerged as an important research target due to its potential role in metabolic diseases, atherosclerosis, neurodegenerative diseases, and stroke . It is highly expressed in the gastrointestinal tract and lung tissue, with lower expression in the heart and brain .

What are the primary research applications for FFAR4 antibodies?

FFAR4 antibodies are used in multiple research applications including:

• Western blot analysis to detect FFAR4 protein expression in various tissues and cell lines

• Immunofluorescence/immunohistochemistry to determine tissue localization

• Flow cytometry for cell surface detection on living cells

• Immunoprecipitation to study protein-protein interactions

These applications help researchers investigate FFAR4's role in diabetes, cardiovascular disease, neuroinflammation, and acute kidney injury .

What should researchers know about FFAR4 expression patterns?

FFAR4 expression has been documented in:

• Gastrointestinal tract (highest expression)

• Lung tissue (high expression)

• Heart (moderate expression)

• Brain (lower but significant expression)

• Cardiac myocytes and fibroblasts

• Macrophages and microglia

• Tubular epithelial cells in kidneys

Of particular interest, FFAR4 is expressed abundantly in the S2 and S3 segments of proximal tubules in the kidney and has been detected in neurons and microglia after ischemic brain injury .

Why is antibody validation especially critical for FFAR4 research?

Multiple studies have highlighted significant concerns about the reliability of commercially available FFAR4 antibodies. Research from Millipore Sigma (SAB4501490) and Santa Cruz BioTechnology (SC-390752) antibodies showed that these antibodies failed to demonstrate specificity when tested with FFAR4 knockout mouse models . This is consistent with known challenges in GPCR antibody development.

Researchers should implement rigorous validation protocols:

• Testing with FFAR4 knockout tissues or cells

• Confirming specificity using alternative methods (e.g., RT-qPCR)

• Performing appropriate blocking controls

• Using multiple antibodies targeting different epitopes when possible

How can researchers properly validate FFAR4 antibodies using genetic controls?

Proper validation requires comparison between wild-type and FFAR4 knockout samples:

Methodological Steps:

• Obtain tissue/cell samples from both wild-type and FFAR4-KO models

• Process samples identically for western blot, immunofluorescence, or other applications

• Confirm genotypes via RT-qPCR analysis of FFAR4 mRNA expression

• Test the antibody against both sample types in parallel

• Look for differential signal patterns that confirm specificity

The study by Zhang et al. demonstrated that when properly validated using FFAR4-KO mice, commercially available antibodies showed identical immunoreactive bands across both wild-type and knockout samples, suggesting non-specificity .

What alternative methods can complement or replace antibody-based detection of FFAR4?

Due to antibody reliability concerns, researchers should consider these alternatives:

For critical experiments, researchers should confirm findings using at least two independent methods .

How does FFAR4 signaling interact with inflammatory pathways in neurodegenerative research?

FFAR4 in microglia has emerged as a key regulator of neuroinflammation. Research indicates:

• Signaling Mechanisms: FFAR4 activates β-arrestin-2-dependent pathways that inhibit NF-κB activation, confirmed by immunoprecipitation assays demonstrating direct FFAR4/β-arrestin-2 interactions .

• Experimental Approaches:

  • CUT&RUN (cleavage under targets and release using nuclease) assays have demonstrated that FFAR4 knockdown increases NF-κB binding to the IFN-β promoter

  • Pretreatment with DHA (docosahexaenoic acid) or PDTC (pyrrolidine dithiocarbamate) attenuates palmitic acid-induced NF-κB activation and inflammatory cytokine production in microglia

• Methodological Recommendation: When studying FFAR4's anti-inflammatory effects, researchers should consider both NF-κB-dependent and independent pathways, as DHA (which activates FFAR4) shows broader inhibitory effects on inflammatory signaling compared to direct NF-κB inhibitors .

What experimental design considerations are essential when studying FFAR4 in cardiac ischemia/reperfusion models?

When studying FFAR4 in cardiac models, researchers should consider:

• Model Selection:

  • Transient coronary artery ligation is an established model for cardiac I/R injury

  • Both male and female mice should be included due to potential sex differences in FFAR4 function

• Genetic Approaches:

  • Systemic FFAR4 knockout models allow assessment of global FFAR4 functions

  • Cell-specific FFAR4 overexpression (e.g., using AAV9-cTnt-Ffar4 vectors) enables targeted cardiac myocyte studies

  • Validation of genetic modifications should be performed by qRT-PCR rather than relying on antibody detection

• Outcome Measurements:

  • Functional recovery assessment through echocardiography

  • Transcriptome analysis of infarcted vs. non-infarcted regions

  • Assessment of mitochondrial metabolism and AMPK signaling pathways

  • Monitoring of inflammatory processes and cellular senescence markers

How can researchers address the challenge of detecting endogenous FFAR4 protein in brain tissue?

Detection of endogenous FFAR4 in neural tissues presents unique challenges:

• Combined Approach Strategy:

  • Use RT-qPCR to confirm gene expression at the mRNA level

  • Implement RNAscope or other in-situ hybridization techniques for cellular localization

  • Consider single-cell RNA sequencing to identify specific cell populations expressing FFAR4

  • Use multiple antibodies targeting different epitopes with appropriate knockout controls

• Technical Refinements:

  • For protein extraction from brain tissue, optimize membrane protein enrichment protocols

  • Consider crosslinking methods that preserve protein-protein interactions

  • Implement tissue clearing techniques for improved immunofluorescence detection in thick sections

  • Validate findings through functional assays (Ca²⁺ signaling, cAMP responses)

How does FFAR4 activation influence cellular senescence pathways in acute kidney injury?

FFAR4 has been identified as a key regulator of cellular senescence in acute kidney injury:

• Signaling Mechanisms:

  • FFAR4 activation by TUG-891 upregulates aging-related SirT3 protein

  • This occurs through Gq subunit-mediated CaMKKβ/AMPK signaling

  • The pathway regulates senescence markers including p53, p21, Lamin B1, phospho-histone H2A.X, and phospho-Rb

• Experimental Evidence:

  • FFAR4 knockout aggravates cisplatin-induced senescence in tubular epithelial cells

  • Increased senescence-associated β-galactosidase (SA-β-gal) activity in FFAR4-KO mice

  • Elevated secretory phenotype IL-6 levels in the absence of FFAR4

• Methodological Approach:

  • Utilize multiple AKI models (cisplatin, sepsis, ischemia/reperfusion injury)

  • Implement both systemic and conditional tubular epithelial cell-specific knockout models

  • Measure kidney function (BUN, serum creatinine) alongside histopathological analysis

  • Assess tubular injury markers (NGAL, KIM1) by qRT-PCR

What are the methodological considerations when analyzing FFAR4's role in metabolic disease and atherosclerosis?

Research on FFAR4 in metabolic disease requires careful experimental design:

• In Vitro Approaches:

  • Human aortic endothelial cells (HAECs) treated with oxidized LDL provide a model for studying FFAR4's atheroprotective effects

  • FFAR4 activation by GW9508 and TUG-891 prevents monocyte attachment and reduces oxidative stress

  • Measure changes in adhesion molecules (VCAM-1, E-selectin) and transcription factors (KLF2)

• Mechanistic Considerations:

  • FFAR4 activation reduces cellular senescence and prevents cell cycle arrest caused by oxidized LDL

  • This occurs through reduction of senescence-associated beta-galactosidase and regulators like p53

  • Nuclear factor erythroid 2-related factor 2 increases production of antioxidant proteins

• Synergistic Pathway Analysis:

  • FFAR4 and PPARγ signaling work synergistically to improve insulin sensitivity

  • FFAR4 is a PPARγ target gene

  • FFAR4 activation blocks ERK-mediated inhibitory phosphorylation of PPARγ-Ser273

  • Consider combination therapy approaches using both FFAR4 and PPARγ agonists

What approaches are recommended for investigating FFAR4 function in neurological disorders with metabolic components?

The study of FFAR4 in neurological disorders with metabolic components requires integrative approaches:

• Model Selection:

  • Metabolic syndrome (MetS) mice models show reduced Ffar4 expression with cognitive impairment

  • Microglia-specific Ffar4 knockout models are valuable for studying neuroinflammatory mechanisms

  • Consider models with both metabolic dysfunction and neurological phenotypes

• Mechanistic Investigation:

  • Assess direct interactions between Ffar4 and β-arrestin-2 via immunoprecipitation assays

  • Examine NF-κB activation patterns and binding to inflammatory gene promoters

  • Evaluate both canonical and non-canonical inflammatory signaling pathways

• Therapeutic Targeting:

  • Compare FFAR4 agonists (like DHA) with direct NF-κB inhibitors (like PDTC)

  • Assess effects on IFN-β production and inflammatory cytokine profiles

  • Measure downstream effects on JAK/STAT signaling pathways

How can single-cell and spatial transcriptomics advance FFAR4 research beyond antibody limitations?

Given the challenges with FFAR4 antibodies, emerging transcriptomic approaches offer promising alternatives:

• Single-Cell RNA Sequencing Applications:

  • Precise identification of cell populations expressing FFAR4

  • Analysis of expression patterns across diverse tissue environments

  • Correlation with other receptors and signaling components

  • Public single-cell RNA databases reveal FFAR4 expression in S2 and S3 segments of proximal tubules

• Spatial Transcriptomics Benefits:

  • Preservation of tissue architecture and spatial relationships

  • Mapping of FFAR4 expression in complex tissues like brain

  • Correlation with regional pathological changes

  • Integration with other -omics datasets

• Implementation Strategy:

  • Begin with single-cell RNA-seq to identify FFAR4-expressing cell populations

  • Follow with spatial transcriptomics to map expression patterns within tissues

  • Validate findings with in-situ hybridization techniques

  • Correlate with functional assays measuring FFAR4-dependent signaling

What genetic engineering approaches are recommended for studying FFAR4 when antibody detection is unreliable?

To circumvent antibody limitations, consider these genetic engineering strategies:

• Reporter Gene Systems:

  • CRISPR-mediated knock-in of fluorescent reporters (GFP, mCherry) fused to FFAR4

  • Creation of FFAR4 promoter-driven reporter constructs

  • Bioluminescence resonance energy transfer (BRET) systems for studying receptor interactions

• Conditional Knockout Models:

  • Cell-type specific Cre-loxP systems for targeted FFAR4 deletion

  • Inducible knockout models for temporal control

  • FFAR4 floxed mice models have been developed and validated

• Overexpression Approaches:

  • Adeno-associated virus (AAV) vectors for tissue-specific overexpression

  • AAV9-cTnt-Ffar4 has been used successfully for cardiac-specific expression

  • Validation should include qRT-PCR rather than antibody detection

How should researchers interpret contradictory findings in FFAR4 research literature?

When faced with contradictory findings, consider these analytical approaches:

• Antibody Validation Assessment:

  • Evaluate whether studies properly validated their antibodies using genetic controls

  • Consider findings from studies using FFAR4-KO mice as gold standard controls

  • Studies relying solely on commercial antibodies without validation should be interpreted cautiously

• Model System Differences:

  • Cell lines vs. primary cells vs. in vivo models may show different FFAR4 functions

  • Species differences (human vs. mouse vs. rat) might contribute to conflicting results

  • Consider sex differences, as FFAR4 function may vary between males and females

• Experimental Methodology Analysis:

  • Evaluate differences in experimental conditions (ligand concentration, treatment duration)

  • Consider the specificity of agonists/antagonists used

  • Assess differences in readout assays and their sensitivity

  • Re-evaluate findings using non-antibody based approaches when possible